Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells.

Spagnuolo M, Regazzo G, De Dominici M, Sacconi A, Pelosi A, Korita E, Marchesi F, Pisani F, Magenta A, Lulli V, Cordone I, Mengarelli A, Strano S, Blandino G, Rizzo MG, Calabretta B.

Haematologica. 2018 Aug 3. pii: haematol.2018.191213. doi: 10.3324/haematol.2018.191213. [Epub ahead of print]

2.

Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.

Donzelli S, Milano E, Pruszko M, Sacconi A, Masciarelli S, Iosue I, Melucci E, Gallo E, Terrenato I, Mottolese M, Zylicz M, Zylicz A, Fazi F, Blandino G, Fontemaggi G.

Breast Cancer Res. 2018 Jun 19;20(1):59. doi: 10.1186/s13058-018-0990-2.

3.

Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.

Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, Donzelli S, Marino M, Ercolani C, Di Benedetto A, Blandino G, Ciliberto G, Mengarelli A, Rizzo MG.

J Exp Clin Cancer Res. 2018 May 2;37(1):95. doi: 10.1186/s13046-018-0768-5.

4.

Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.

Di Agostino S, Valenti F, Sacconi A, Fontemaggi G, Pallocca M, Pulito C, Ganci F, Muti P, Strano S, Blandino G.

Theranostics. 2018 Feb 12;8(7):1850-1868. doi: 10.7150/thno.22167. eCollection 2018.

5.

hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.

Di Modugno F, Caprara V, Chellini L, Tocci P, Spadaro F, Ferrandina G, Sacconi A, Blandino G, Nisticò P, Bagnato A, Rosanò L.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3132-3137. doi: 10.1073/pnas.1715998115. Epub 2018 Feb 8.

6.

The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex.

Verduci L, Ferraiuolo M, Sacconi A, Ganci F, Vitale J, Colombo T, Paci P, Strano S, Macino G, Rajewsky N, Blandino G.

Genome Biol. 2017 Dec 20;18(1):237. doi: 10.1186/s13059-017-1368-y.

7.

MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration.

Frixa T, Sacconi A, Cioce M, Roscilli G, Ferrara FF, Aurisicchio L, Pulito C, Telera S, Carosi M, Muti P, Strano S, Donzelli S, Blandino G.

Carcinogenesis. 2018 Feb 9;39(2):293-304. doi: 10.1093/carcin/bgx134.

PMID:
29236960
8.

Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells.

Dinami R, Buemi V, Sestito R, Zappone A, Ciani Y, Mano M, Petti E, Sacconi A, Blandino G, Giacca M, Piazza S, Benetti R, Schoeftner S.

Oncotarget. 2017 Sep 23;8(56):95674-95691. doi: 10.18632/oncotarget.21180. eCollection 2017 Nov 10.

9.

MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study.

Muti P, Donzelli S, Sacconi A, Hossain A, Ganci F, Frixa T, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene J, Yarden Y, Blandino G.

Carcinogenesis. 2018 Feb 9;39(2):98-108. doi: 10.1093/carcin/bgx126.

PMID:
29126102
10.

Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence.

Ganci F, Sacconi A, Manciocco V, Covello R, Benevolo M, Rollo F, Strano S, Valsoni S, Bicciato S, Spriano G, Muti P, Fontemaggi G, Blandino G.

Mod Pathol. 2017 Oct;30(10):1387-1401. doi: 10.1038/modpathol.2017.62. Epub 2017 Jul 21.

PMID:
28731048
11.

Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities.

Pulito C, Mori F, Sacconi A, Goeman F, Ferraiuolo M, Pasanisi P, Campagnoli C, Berrino F, Fanciulli M, Ford RJ, Levrero M, Pediconi N, Ciuffreda L, Milella M, Steinberg GR, Cioce M, Muti P, Strano S, Blandino G.

Cell Discov. 2017 Jul 4;3:17022. doi: 10.1038/celldisc.2017.22. eCollection 2017.

12.

In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells.

Rizzo A, Donzelli S, Girgenti V, Sacconi A, Vasco C, Salmaggi A, Blandino G, Maschio M, Ciusani E.

J Exp Clin Cancer Res. 2017 Jun 6;36(1):76. doi: 10.1186/s13046-017-0546-9.

13.

MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma.

Fattore L, Sacconi A, Mancini R, Ciliberto G.

Cytokine Growth Factor Rev. 2017 Aug;36:39-48. doi: 10.1016/j.cytogfr.2017.05.003. Epub 2017 May 17. Review.

PMID:
28551321
14.

AMPK β1 reduces tumor progression and improves survival in p53 null mice.

Houde VP, Donzelli S, Sacconi A, Galic S, Hammill JA, Bramson JL, Foster RA, Tsakiridis T, Kemp BE, Grasso G, Blandino G, Muti P, Steinberg GR.

Mol Oncol. 2017 Sep;11(9):1143-1155. doi: 10.1002/1878-0261.12079. Epub 2017 Jun 28.

15.

Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.

Bellissimo T, Ganci F, Gallo E, Sacconi A, Tito C, De Angelis L, Pulito C, Masciarelli S, Diso D, Anile M, Petrozza V, Giangaspero F, Pescarmona E, Facciolo F, Venuta F, Marino M, Blandino G, Fazi F.

Mol Cancer. 2017 May 10;16(1):88. doi: 10.1186/s12943-017-0655-2.

16.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.

Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

17.

MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer.

Canu V, Sacconi A, Lorenzon L, Biagioni F, Lo Sardo F, Diodoro MG, Muti P, Garofalo A, Strano S, D'Errico A, Grazi GL, Cioce M, Blandino G.

Oncotarget. 2017 May 2;8(18):29540-29557. doi: 10.18632/oncotarget.15290.

18.

MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.

Lo Sardo F, Forcato M, Sacconi A, Capaci V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S, Bicciato S, Blandino G.

Carcinogenesis. 2017 Jan;38(1):64-75. doi: 10.1093/carcin/bgw110. Epub 2016 Oct 17.

PMID:
27797825
19.

Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models.

Nuvoli B, Sacconi A, Cortese G, Germoni S, Murer B, Galati R.

Oncotarget. 2016 Jul 26;7(30):47116-47126. doi: 10.18632/oncotarget.9964.

20.

Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects.

Mori F, Ferraiuolo M, Santoro R, Sacconi A, Goeman F, Pallocca M, Pulito C, Korita E, Fanciulli M, Muti P, Blandino G, Strano S.

Oncotarget. 2016 Apr 12;7(15):20532-48. doi: 10.18632/oncotarget.7978.

21.

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.

Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A, Blandino G, Bagnato A.

Oncotarget. 2016 Jan 26;7(4):4009-23. doi: 10.18632/oncotarget.6546.

22.

Antibody Array as a Tool for Screening of Natural Agents in Cancer Chemoprevention.

Pulito C, Sacconi A, Korita E, Maidecchi A, Strano S.

Methods Mol Biol. 2016;1379:189-99. doi: 10.1007/978-1-4939-3191-0_17.

PMID:
26608301
23.

Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors.

Bellissimo T, Russo E, Ganci F, Vico C, Sacconi A, Longo F, Vitolo D, Anile M, Disio D, Marino M, Blandino G, Venuta F, Fazi F.

Cancer Biol Ther. 2016;17(1):79-82. doi: 10.1080/15384047.2015.1108493.

24.

Epigenetic silencing of miR-145-5p contributes to brain metastasis.

Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, Roscilli G, Aurisicchio L, Facciolo F, Pompili A, Carosi MA, Pescarmona E, Segatto O, Pond G, Muti P, Telera S, Strano S, Yarden Y, Blandino G.

Oncotarget. 2015 Nov 3;6(34):35183-201. doi: 10.18632/oncotarget.5930.

25.

Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.

Pulito C, Mori F, Sacconi A, Casadei L, Ferraiuolo M, Valerio MC, Santoro R, Goeman F, Maidecchi A, Mattoli L, Manetti C, Di Agostino S, Muti P, Blandino G, Strano S.

Oncotarget. 2015 Jul 20;6(20):18134-50.

26.

miR-181c associates with tumor relapse of high grade osteosarcoma.

Mori F, Sacconi A, Canu V, Ganci F, Novello M, Anelli V, Covello R, Ferraresi V, Muti P, Biagini R, Blandino G, Strano S.

Oncotarget. 2015 Jun 10;6(16):13946-61.

27.

Cdx2 polymorphism affects the activities of vitamin D receptor in human breast cancer cell lines and human breast carcinomas.

Pulito C, Terrenato I, Di Benedetto A, Korita E, Goeman F, Sacconi A, Biagioni F, Blandino G, Strano S, Muti P, Mottolese M, Falvo E.

PLoS One. 2015 Apr 7;10(4):e0124894. doi: 10.1371/journal.pone.0124894. eCollection 2015.

28.

Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.

Valenti F, Ganci F, Fontemaggi G, Sacconi A, Strano S, Blandino G, Di Agostino S.

Oncotarget. 2015 Mar 20;6(8):5547-66.

29.

MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma.

Ganci F, Sacconi A, Manciocco V, Sperduti I, Battaglia P, Covello R, Muti P, Strano S, Spriano G, Fontemaggi G, Blandino G.

Head Neck. 2016 Apr;38 Suppl 1:E189-97. doi: 10.1002/hed.23969. Epub 2015 Jun 24.

PMID:
25532855
30.

Binding of a monoclonal antibody to the phospholamban cytoplasmic domain interferes with the channel activity of phospholamban reconstituted in a tethered bilayer lipid membrane.

Smeazzetto S, Sacconi A, Schwan AL, Margheri G, Tadini-Buoninsegni F.

Langmuir. 2014 Sep 2;30(34):10384-8. doi: 10.1021/la501660u. Epub 2014 Aug 20.

PMID:
25121716
31.

Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study.

Muti P, Sacconi A, Hossain A, Donzelli S, Ben Moshe NB, Ganci F, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene J, Yarden Y, Blandino G.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2471-81. doi: 10.1158/1055-9965.EPI-14-0398. Epub 2014 Jul 29.

32.

Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells.

Cioce M, Valerio M, Casadei L, Pulito C, Sacconi A, Mori F, Biagioni F, Manetti C, Muti P, Strano S, Blandino G.

Oncotarget. 2014 Jun 30;5(12):4129-43.

33.

miR-155 drives telomere fragility in human breast cancer by targeting TRF1.

Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeftner S.

Cancer Res. 2014 Aug 1;74(15):4145-56. doi: 10.1158/0008-5472.CAN-13-2038. Epub 2014 May 29.

34.

MicroRNA expression profiling of thymic epithelial tumors.

Ganci F, Vico C, Korita E, Sacconi A, Gallo E, Mori F, Cambria A, Russo E, Anile M, Vitolo D, Pescarmona E, Blandino R, Facciolo F, Venuta F, Blandino G, Marino M, Fazi F.

Lung Cancer. 2014 Aug;85(2):197-204. doi: 10.1016/j.lungcan.2014.04.008. Epub 2014 Apr 29.

PMID:
24863004
35.

MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.

Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, Capodanno A, Salvini J, Corgna E, Cupini S, Barbara C, Fontanini G, Crinò L, Blandino G.

Clin Colorectal Cancer. 2014 Mar;13(1):37-45.e4. doi: 10.1016/j.clcc.2013.11.006. Epub 2013 Nov 14.

PMID:
24503111
36.

Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.

Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, Carosi MA, Blandino R, Panebianco V, Facciolo F, Visca P, Volinia S, Muti P, Strano S, Croce CM, Pass HI, Blandino G.

Oncogene. 2014 Nov 13;33(46):5319-31. doi: 10.1038/onc.2013.476. Epub 2013 Nov 18.

37.

Enhanced adsorption of Ca-ATPase containing vesicles on a negatively charged solid-supported-membrane for the investigation of membrane transporters.

Sacconi A, Moncelli MR, Margheri G, Tadini-Buoninsegni F.

Langmuir. 2013 Nov 12;29(45):13883-9. doi: 10.1021/la4034386. Epub 2013 Oct 31.

PMID:
24131452
38.

Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.

Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, Spriano G, Fontemaggi G, Blandino G.

Ann Oncol. 2013 Dec;24(12):3082-8. doi: 10.1093/annonc/mdt380. Epub 2013 Oct 9.

39.

miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer.

Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G.

Cell Death Dis. 2012 Nov 15;3:e423. doi: 10.1038/cddis.2012.160.

40.

Hippo and rassf1a Pathways: A Growing Affair.

Fausti F, Di Agostino S, Sacconi A, Strano S, Blandino G.

Mol Biol Int. 2012;2012:307628. doi: 10.1155/2012/307628. Epub 2012 Jul 5.

41.

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S, Manetti C, Citro G, Muti P, Strano S.

Nat Commun. 2012 May 29;3:865. doi: 10.1038/ncomms1859.

PMID:
22643892
42.

p95HER2 truncated form in resected non-small cell lung cancer.

Cappuzzo F, Cho YG, Sacconi A, Alì G, Siclari O, Incarbone M, Destro A, Terracciano L, Fontanini G, Marchetti A, Roncalli M, Varella-Garcia M.

J Thorac Oncol. 2012 Mar;7(3):520-7. doi: 10.1097/JTO.0b013e318249e13f. Erratum in: J Thorac Oncol. 2012 Jun;7(6):1065.

43.

Analytical considerations for mass spectrometry profiling in serum biomarker discovery.

Whiteley GR, Colantonio S, Sacconi A, Saul RG.

Clin Lab Med. 2009 Mar;29(1):57-69. doi: 10.1016/j.cll.2009.01.003. Review.

PMID:
19389551
44.

Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.

Felici A, Di Segni S, Milella M, Colantonio S, Sperduti I, Nuvoli B, Contestabile M, Sacconi A, Zaratti M, Citro G, Cognetti F.

Clin Pharmacokinet. 2009;48(2):131-41. doi: 10.2165/0003088-200948020-00005.

PMID:
19271785

Supplemental Content

Loading ...
Support Center